Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.64 |
| ▸ | XDH | P47989 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Picroside I SCHEMBL14361938 | 1.00 | HSP90AA1 (0.64) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL29425973 | 0.93 | HSP90AA1 (0.74) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL29425942 | 0.90 | HSP90AA1 (0.62) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL9057920 | 0.89 | HSP90AA1 (0.64) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL30519385 | 0.86 | HSP90AA1 (0.64) | HSP90AA1XDHPRKCACYP19A1LDHA | |
| SCHEMBL422812 | 0.81 | HSP90AA1 (0.63) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL9057747 | 0.80 | KDM4E (0.59) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL9056457 | 0.80 | KDM4E (0.59) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL29426089 | 0.80 | HSP90AA1 (0.73) | HSP90AA1XDHKDM4EGLACYP3A4 | |
| SCHEMBL29503004 | 0.79 | L3MBTL1 (0.62) | HSP90AA1XDHKDM4EGLACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086871-A1 | ANTI-AGEING COMPOUNDS, USES THEREFOR, METHOD FOR IDENTIFYING, AND COMPOSITIONS CONTAINING | Centre for Translational Stem Cell Biology Limited (CN) | 2026-04-30 | — | — | WO | claimed |
| EP-4326280-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PICROSIDE | Goldlake Lifesciences Pvt Ltd (IN) | 2025-11-12 | — | — | EP | claimed |
| CN-119837807-A | Rhizoma picrorhizae extract and its function and use | 云南英格生物技术有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119667007-A | Method for measuring content of iridoid components | 鲁南制药集团股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| US-20240350441-A1 | PHARMACEUTICAL FORMULATION AND A PROCESS FOR ITS PREPARATION | Goldlake Lifesciences Pvt Ltd (IN) | 2024-10-24 | — | — | US | claimed |
| EP-4440554-A1 | A PHARMACEUTICAL FORMULATION AND A PROCESS FOR ITS PREPARATION | Sava Healthcare Ltd (IN) | 2024-10-09 | — | — | EP | claimed |
| CN-118354764-A | Pharmaceutical preparation and method for producing the same | 萨瓦医疗保健有限公司 | 2024-07-16 | — | — | CN | claimed |
| CN-117871726-A | Bone clearing powder particle standard reference substance and preparation method and application thereof | 赣江中药创新中心 | 2024-04-12 | — | — | CN | claimed |
| US-20240091244-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PICROSIDE | Goldlake Lifesciences Pvt Ltd (IN) | 2024-03-21 | — | — | US | claimed |
| EP-4326280-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PICROSIDE | Sava Healthcare Ltd (IN) | 2024-02-28 | — | — | EP | claimed |
| CN-117571852-A | Method for simultaneously and qualitatively detecting multiple components in heart-calming oral liquid | 健康元药业集团股份有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-117343112-A | Preparation method of picrorhiza rhizome multi-component compound | 山东新时代药业有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-117177757-A | Pharmaceutical composition comprising picroside | 萨瓦医疗保健有限公司 | 2023-12-05 | — | — | CN | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| WO-2023099968-A1 | A PHARMACEUTICAL FORMULATION AND A PROCESS FOR ITS PREPARATION | SAVA HEALTHCARE LTD (IN) | 2023-06-08 | — | — | WO | claimed |
| CN-112946139-B | Fingerprint spectrum of rhizoma picrorhizae medicinal preparation, and establishing method and application thereof | 华润三九医药股份有限公司 | 2023-03-21 | — | — | CN | claimed |
| WO-2022224025-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PICROSIDE | SAVA HEALTHCARE LIMITED (IN) | 2022-10-27 | — | — | WO | claimed |
| WO-2026086871-A1 | ANTI-AGEING COMPOUNDS, USES THEREFOR, METHOD FOR IDENTIFYING, AND COMPOSITIONS CONTAINING | Centre for Translational Stem Cell Biology Limited (CN) | 2026-04-30 | — | — | WO | disclosed |
| EP-3409766-B1 | AN ESTERASE THAT IS CAPABLE OF CONVERTING IRIDOIDS AND SECO-IRIDOIDS | N ZYME BIOTEC GMBH (DE) | 2022-03-09 | — | — | EP | disclosed |
| WO-2022018606-A1 | MODULATION OF NCRNAS, LYMPHOCYTES, NEUTROPHILS, INFLAMMASOMES AND P53 | MEDASANI MUNISEKHAR (IN) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350441-A1 | PHARMACEUTICAL FORMULATION AND A PROCESS FOR ITS PREPARATION | MYD88, NFATC1, CCR6 | HSP90AA1 2862/4885XDH 1502/4885KDM4E 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.